First Patient Dosed with new Formulation of AO-252

AI SummaryClose X

Coiled Therapeutics PLC has dosed the first patient in the United States with an optimised lipid-based oral formulation of AO-252, a TACC3 inhibitor, which showed no treatment-related adverse safety findings. This new formulation aims to improve drug exposure and overcome absorption limitations observed with the previous tablet formulation, which achieved an 80% Clinical Benefit Rate in a twice-daily dosing cohort. The company plans to initiate dose-expansion cohorts in ovarian and prostate cancer, targeting up to 30 patients by Q4 2026, and expects initial safety and pharmacokinetic data from the new formulation in Q4 2026, which could support further engagement with interested pharmaceutical companies.

Disclaimer*

UK 100

Latest directors dealings